View Daily Data Tracking History
View Bill Text
View Statement of Purpose / Fiscal Impact
H0429.................................................by HEALTH AND WELFARE
CONTROLLED SUBSTANCES - Amends existing law to add the drug ketamine to
schedule III controlled substances; and to reschedule the drug dronabinol
from schedule II to schedule III controlled substances.
01/25 House intro - 1st rdg - to printing
01/26 Rpt prt - to Health/Wel
02/15 Rpt out - rec d/p - to 2nd rdg
02/16 2nd rdg - to 3rd rdg
02/21 3rd rdg - PASSED - 67-0-3
AYES -- Alltus, Barrett, Bell, Bieter, Black, Boe, Bruneel,
Callister, Campbell, Chase, Cheirrett, Clark, Cuddy, Deal, Denney,
Ellsworth, Field(13), Field(20), Gagner, Geddes, Gould, Hadley,
Hammond, Hansen(23), Hansen(29), Henbest, Hornbeck, Jaquet, Jones,
Judd, Kellogg, Kempton, Kendell, Kunz, Lake, Linford, Loertscher,
Mader, Marley, McKague, Meyer, Montgomery, Mortensen, Moss, Moyle,
Pearce, Pischner, Pomeroy, Reynolds, Ridinger, Ringo, Robison, Sali,
Schaefer, Sellman, Shepherd, Smith, Smylie, Stevenson, Stoicheff,
Stone, Taylor, Tilman, Trail(Miller), Wheeler, Wood, Zimmermann
NAYS -- None
Absent and excused -- Barraclough, Crow, Mr Speaker
Floor Sponsor - Bieter
Title apvd - to Senate
02/22 Senate intro - 1st rdg - to Health/Wel
02/25 Rpt out - rec d/p - to 2nd rdg
02/28 2nd rdg - to 3rd rdg
03/24 3rd rdg - PASSED - 35-0-0
AYES -- Andreason, Boatright, Branch, Bunderson, Burtenshaw, Cameron,
Crow, Danielson, Darrington, Davis, Deide, Dunklin, Frasure, Geddes,
Hawkins, Ingram, Ipsen, Keough, King-Barrutia, Lee, McLaughlin, Noh,
Parry, Richardson, Riggs, Risch, Sandy, Schroeder, Sorensen, Stegner,
Stennett, Thorne, Wheeler, Whitworth, Williams
NAYS -- None
Absent and excused -- None
Floor Sponsor - Wheeler
Title apvd - to House
03/27 To enrol
03/28 Rpt enrol - Sp signed
03/29 Pres signed
03/30 To Governor
Governor signed
Session Law Chapter 110
Effective: 07/01/00
H0429
|||| LEGISLATURE OF THE STATE OF IDAHO ||||
Fifty-fifth Legislature Second Regular Session - 2000
IN THE HOUSE OF REPRESENTATIVES
HOUSE BILL NO. 429
BY HEALTH AND WELFARE COMMITTEE
1 AN ACT
2 RELATING TO CONTROLLED SUBSTANCES; AMENDING SECTION 37-2707, IDAHO CODE, TO
3 REMOVE THE DRUG DRONABINOL FROM SCHEDULE II AND TO MAKE TECHNICAL CORREC-
4 TIONS; AMENDING SECTION 37-2709, IDAHO CODE, TO ADD THE DRUGS KETAMINE AND
5 DRONABINOL TO SCHEDULE III AND TO MAKE TECHNICAL CORRECTIONS; AND PROVID-
6 ING AN EFFECTIVE DATE.
7 Be It Enacted by the Legislature of the State of Idaho:
8 SECTION 1. That Section 37-2707, Idaho Code, be, and the same is hereby
9 amended to read as follows:
10 37-2707. SCHEDULE II. (a) Schedule II shall consist of the drugs and
11 other substances, by whatever official name, common or usual name, chemical
12 name, or brand name designated, listed in this section.
13 (b) Substances, vegetable origin or chemical synthesis. Unless specifi-
14 cally excepted or unless listed in another schedule, any of the following sub-
15 stances whether produced directly or indirectly by extraction from substances
16 of vegetable origin, or independently by means of chemical synthesis, or by a
17 combination of extraction and chemical synthesis:
18 (1) Opium and opiate, and any salt, compound, derivative, or preparation
19 of opium or opiate, excluding apomorphine, dextrorphan, nalbuphine,
20 nalmefene, naloxone, naltrexone and their respective salts, but including
21 the following:
22 1. Raw opium;
23 2. Opium extracts;
24 3. Opium fluid extracts;
25 4. Powdered opium;
26 5. Granulated opium;
27 6. Tincture of opium;
28 7. Codeine;
29 8. Ethylmorphine;
30 9. Etorphine hydrochloride;
31 10. Hydrocodone;
32 11. Hydromorphone;
33 12. Metopon;
34 13. Morphine;
35 14. Oxycodone;
36 15. Oxymorphone;
37 16. Thebaine.
38 (2) Any salt, compound, derivative, or preparation thereof which is chem-
39 ically equivalent or identical with any of the substances referred to in
40 paragraph (b) (1) of this section, except that these substances shall not
41 include the isoquinoline alkaloids of opium.
42 (3) Opium poppy and poppy straw.
43 (4) Coca leaves and any salt, compound, derivative, or preparation of
2
1 coca leaves, and any salt, compound, derivative, or preparation thereof
2 which is chemically equivalent or identical with any of these substances,
3 but not including decocainized coca leaves or extractions which do not
4 contain cocaine or ecgonine.
5 (5) Methylbenzoylecgonine (Cocaine - its salts, optical isomers, and
6 salts of optical isomers).
7 (6) Concentrate of poppy straw (the crude extract of poppy straw in
8 either liquid, solid or powder form which contains the phenanthrine
9 alkaloids of the opium poppy).
10 (c) Any of the following opiates, including their isomers, esters,
11 ethers, salts, and salts of isomers, whenever the existence of these isomers,
12 esters, ethers and salts is possible within the specific chemical designation,
13 unless specifically excepted or unless listed in another schedule:
14 (1) Alfentanil;
15 (2) Alphaprodine;
16 (3) Anileridine;
17 (4) Bezitramide;
18 (5) Bulk Dextropropoxyphene (nondosage forms);
19 (6) Carfentanil;
20 (7) Dihydrocodeine;
21 (8) Diphenoxylate;
22 (9) Fentanyl;
23 (10) Isomethadone;
24 (11) Levo-alphacetylmethadol (also known as levo-alpha-acetylmethadol,
25 levomethadyl acetate, LAAM);
26 (12) Levomethorphan;
27 (13) Levorphanol;
28 (14) Metazocine;
29 (15) Methadone;
30 (16) Methadone -- Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl
31 butane;
32 (17) Moramide -- Intermediate, 2-methyl-3-morpholino-1, 1-diphenyl
33 propane-carboxylic acid;
34 (18) Pethidine (meperidine);
35 (19) Pethidine -- Intermediate -- A, 4-cyano-1-methyl-4-phenylpiperidine;
36 (20) Pethidine -- Intermediate -- B, ethyl-4-phenylpiperidine-4-
37 carboxylate;
38 (21) Pethidine -- Intermediate -- C, 1-methyl-4-phenylpiperidine-4-carbo-
39 xylic acid;
40 (22) Phenazocine;
41 (23) Piminodine;
42 (24) Racemethorphan;
43 (25) Racemorphan;
44 (26) Sufentanil.
45 (d) Stimulants. Unless specifically excepted or unless listed in another
46 schedule, any material, compound, mixture, or preparation which contains any
47 quantity of the following substances having a stimulant effect on the central
48 nervous system:
49 (1) Amphetamine, its salts, optical isomers, and salts of its optical
50 isomers;
51 (2) Methamphetamine, its salts, isomers, and salts of its isomers;
52 (3) Phenmetrazine and its salts;
53 (4) Methylphenidate.
54 (e) Depressants. Unless specifically excepted or unless listed in another
55 schedule, any material, compound, mixture, or preparation which contains any
3
1 quantity of the following substances having a depressant effect on the cen-
2 tral nervous system, including its salts, isomers, and salts of isomers, when-
3 ever the existence of such salts, isomers, and salts of isomers is possible
4 within the specific chemical designation:
5 (1) Amobarbital;
6 (2) Glutethimide;
7 (3) Pentobarbital;
8 (4) Phencyclidine;
9 (5) Secobarbital.
10 (f) Hallucinogenic substances.
11 (1) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gela-
12 tin capsule in a U.S. Food and Drug Administration approved drug product
13 (21 C.F.R. 1308.12 (f)).
14 (2) Nabiline .................................(another name for nabilone:
15 (+)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-
16 dimethyl-9H-dibenzo[b,d]pyran-9-one) (21 C.F.R. 1308.12 (f)).
17 (g) Immediate precursors. Unless specifically excepted or unless listed
18 in another schedule, any material, compound, mixture, or preparation which
19 contains any quantity of the following substances:
20 (1) Immediate precursor to amphetamine and methamphetamine:
21 (a) Anthranilic acid;
22 (b) Ephedrine;
23 (c) Lead acetate;
24 (d) Methylamine;
25 (e) Methyl formamide;
26 (f) N-methylephedrine;
27 (g) Phenylacetic acid;
28 (h) Phenylacetone;
29 (i) Phenylpropanolamine;
30 (j) Pseudoephedrine.
31 Except that any combination or compound containing ephedrine, or any of
32 its salts and isomers, or phenylpropanolamine or its salts and isomers, or
33 pseudoephedrine, or any of its salts and isomers which is prepared for dis-
34 pensing or over-the-counter distribution is not a controlled substance for the
35 purpose of this section, unless such substance is possessed, delivered, or
36 possessed with intent to deliver to another with the intent to manufacture
37 methamphetamine, amphetamine or any other controlled substance in violation of
38 section 37-2732, Idaho Code. For purposes of this provision, the requirements
39 of the uniform controlled substances act shall not apply to a manufacturer,
40 wholesaler or retailer of over-the-counter products containing the listed sub-
41 stances unless such person possesses, delivers, or possesses with intent to
42 deliver to another the over-the-counter product with intent to manufacture a
43 controlled substance.
44 (2) Immediate precursors to phencyclidine (PCP):
45 (a) 1-phenylcyclohexylamine;
46 (b) 1-piperidinocyclohexanecarbonitrile (PCC).
47 SECTION 2. That Section 37-2709, Idaho Code, be, and the same is hereby
48 amended to read as follows:
49 37-2709. SCHEDULE III. (a) Schedule III shall consist of the drugs and
50 other substances, by whatever official name, common or usual name, chemical
51 name, or brand name designated, listed in this section.
52 (b) Stimulants. Unless specifically excepted or unless listed in another
53 schedule, any material, compound, mixture, or preparation which contains any
4
1 quantity of the following substances having a stimulant effect on the central
2 nervous system, including its salts, isomers, (whether optical or geometric),
3 and salts of such isomers whenever the existence of such salts, isomers, and
4 salts of isomers is possible within the specific chemical designation:
5 (1) Those compounds, mixtures, or preparations in dosage unit form con-
6 taining any stimulant substances listed in schedule II which compounds,
7 mixtures, or preparations were listed on August 25, 1971, as excepted com-
8 pounds under C.F.R. Sec. 308.32, and any other drug of the quantitative
9 composition shown in that list for those drugs or which is the same except
10 that it contains a lesser quantity of controlled substances.
11 (2) Benzphetamine;
12 (3) Chlorphentermine;
13 (4) Clortermine;
14 (5) Phendimetrazine.
15 (c) Depressants. Unless listed in another schedule, any material, com-
16 pound, mixture, or preparation which contains any quantity of the following
17 substances having a potential for abuse associated with a depressant effect on
18 the central nervous system:
19 (1) Any compound, mixture or preparation containing:
20 i. Amobarbital;
21 ii. Secobarbital;
22 iii. Pentobarbital or any salt thereof and one (1) or more other
23 active medicinal ingredients which are not listed in any schedule.
24 (2) Any suppository dosage form containing:
25 i. Amobarbital;
26 ii. Secobarbital;
27 iii. Pentobarbital or any salt of any of these drugs and approved by
28 the Food and Drug Administration for marketing only as a suppository.
29 (3) Any substance which contains any quantity of a derivative of
30 barbituric acid or any salt thereof;
31 (4) Chlorhexadol;
32 (5) Ketamine, its salts, isomers, and salts of isomers - 7285. (Some other
33 names for ketamine: ( )-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone).
34 (6) Lysergic acid;
35 (67) Lysergic acid amide;
36 (78) Methyprylon;
37 (89) Sulfondiethylmethane;
38 (910) Sulfonethylmethane;
39 (101) Sulfonmethane;
40 (112) Tiletamine and zolazepam or any salt thereof.
41 (d) Nalorphine.
42 (e) Narcotic drugs. Unless specifically excepted or unless listed in
43 another schedule, any material, compound, mixture, or preparation containing
44 limited quantities of any of the following narcotic drugs, or any salts
45 thereof:
46 (1) Not more than 1.8 grams of codeine, or any of its salts, per 100
47 milliliters or not more than 90 milligrams per dosage unit, with an equal
48 or greater quantity of an isoquinoline alkaloid of opium;
49 (2) Not more than 1.8 grams of codeine, or any of its salts, per 100
50 milliliters or not more than 90 milligrams per dosage unit, with one (1)
51 or more active, nonnarcotic ingredients in recognized therapeutic amounts;
52 (3) Not more than 300 milligrams of dihydrocodeinone, or any of its
53 salts, per 100 milliliters or not more than 15 milligrams per dosage unit,
54 with a fourfold or greater quantity of an isoquinoline alkaloid of opium;
55 (4) Not more than 300 milligrams of dihydrocodeinone, or any of its
5
1 salts, per 100 milliliters or not more than 15 milligrams per dosage unit,
2 with one (1) or more active, nonnarcotic ingredients in recognized thera-
3 peutic amounts;
4 (5) Not more than 1.8 grams of dihydrocodeine, or any of its salts, per
5 100 milliliters or not more than 90 milligrams per dosage unit, with one
6 (1) or more active, nonnarcotic ingredients in recognized therapeutic
7 amounts;
8 (6) Not more than 300 milligrams of ethylmorphine, or any of its salts,
9 per 100 milliliters or not more than 15 milligrams per dosage unit, with
10 one (1) or more ingredients in recognized therapeutic amounts;
11 (7) Not more than 500 milligrams of opium per 100 milliliters or per 100
12 grams, or not more than 25 milligrams per dosage unit, with one (1) or
13 more active, nonnarcotic ingredients in recognized therapeutic amounts;
14 (8) Not more than 50 milligrams of morphine, or any of its salts, per 100
15 milliliters or per 100 grams with one (1) or more active, nonnarcotic
16 ingredients in recognized therapeutic amounts.
17 (f) Anabolic steroids and human growth hormones. Any drug or hormonal
18 substance, chemically and pharmacologically related to testosterone (other
19 than estrogens, progestins and corticosteroids) that promotes muscle growth
20 including any salt, ester or isomer of a drug or substance listed in this
21 paragraph, if that salt, ester or isomer promotes muscle growth.
22 (1) Boldenone;
23 (2) Chlorotestosterone (4-chlortestosterone);
24 (3) Chorionic gonadotropin;
25 (4) Clostebol;
26 (5) Dehydrochlormethyltestosterone;
27 (6) Dihydrotestosterone (4-dihydrotestosterone);
28 (7) Drostanolone;
29 (8) Ethylestrenol;
30 (9) Fluoxymesterone;
31 (10) Formebulone;
32 (11) Human growth hormones;
33 (12) Mesterolone;
34 (13) Methandienone;
35 (14) Methandranone;
36 (15) Methandriol;
37 (16) Methandrostenolone;
38 (17) Methenolone;
39 (18) Methyltestosterone;
40 (19) Mibolerone;
41 (20) Nandrolone;
42 (21) Norethandrolone;
43 (22) Oxandrolone;
44 (23) Oxymesterone;
45 (24) Oxymetholone;
46 (25) Stanolone;
47 (26) Stanozolol;
48 (27) Testolactone;
49 (28) Testosterone;
50 (29) Testosterone cypionate;
51 (30) Testosterone enanthate;
52 (31) Testosterone propionate;
53 (32) Trenbolone.
54 Anabolic steroids that are expressly intended for administration through
55 implants to cattle or other nonhuman species, and that are approved by the
6
1 federal Food and Drug Administration for such use, shall not be classified as
2 controlled substances under this act and shall not be governed by its provi-
3 sions.
4 In addition to the penalties prescribed in article IV of the uniform con-
5 trolled substances act, any person shall be guilty of a felony who prescribes,
6 dispenses, supplies, sells, delivers, manufactures or possesses with the
7 intent to prescribe, dispense, supply, sell, deliver or manufacture anabolic
8 steroids or any other human growth hormone for purposes of enhancing perfor-
9 mance in an exercise, sport or game or hormonal manipulation intended to
10 increase muscle mass, strength or weight without a medical necessity as deter-
11 mined by a physician.
12 (g) Hallucinogenic substances.
13 (1) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gela-
14 tin capsule in the federal Food and Drug Administration approved product -
15 7369. (Some other names for dronabinol: (6aR-trans)
16 -6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo [b,d]pyran-1-ol
17 or (-)-delta-9-(trans)-tetrahydrocannabinol).
18 (h) Other substances. Unless specifically excepted, or unless listed in
19 another schedule, any material, compound, mixture, or preparation which con-
20 tains any quantity of the following substance, including its salts:
21 (1) Butorphanol.
22 (hi) The board may except by rule any compound, mixture, or preparation
23 containing any stimulant or depressant substance listed in subsections (b) and
24 (c) of this section from the application of all or any part of this act if the
25 compound, mixture, or preparation contains one (1) or more active medicinal
26 ingredients not having a stimulant or depressant effect on the central nervous
27 system, and if the admixtures are included therein in combinations, quantity,
28 proportion, or concentration that vitiate the potential for abuse of the sub-
29 stances which have a stimulant or depressant effect on the central nervous
30 system.
31 SECTION 3. This act shall be in full force and effect on and after July
32 1, 2000.
STATEMENT OF PURPOSE
RS09604
The purpose of this proposed legislation is to add the drug
ketamine to Schedule III and reschedule the drug dronabinol
from Schedule II to Schedule III to conform to federal
regulations.
FISCAL IMPACT
There will be no impact on the General Fund, no cost to the
general public or practitioners, and implementation of the
legislation will be from the Board of Pharmacy dedicated funds.
CONTACT: Richard K. "Mick" Markuson, Director
Idaho State Board of Pharmacy
334-2356
STATEMENT OF PURPOSE/FISCAL NOTE H 429